#Roche #primaryprogressiveMS #MS #phase3trial #oralBTKinhibitor #fenebrutinib #primaryprogressivemultiplesclerosis #PPMS #Ocrevus #ocrelizumab #FENtrepidtrial #disabilityprogression #CD20targetingantibody #FENhance1trial #FENhance2trial #clinicalbenefit #diseasemodifyingtherapy
zurl.co/MGaVR
zurl.co/MGaVR
Data builds on Roche's dominance in primary progressive MS
Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.
pharmaphorum.com
February 10, 2026 at 10:17 AM
🔥A new ray of hope for PPMS!
The FENtrepid results comparing Fenebrutinib vs ocrelizumab are so encouraging!
The wonderful podcast👇
ectrims.eu/podcast/episod…
And a summary 👇
The FENtrepid results comparing Fenebrutinib vs ocrelizumab are so encouraging!
The wonderful podcast👇
ectrims.eu/podcast/episod…
And a summary 👇
February 9, 2026 at 12:13 PM
🔥A new ray of hope for PPMS!
The FENtrepid results comparing Fenebrutinib vs ocrelizumab are so encouraging!
The wonderful podcast👇
ectrims.eu/podcast/episod…
And a summary 👇
The FENtrepid results comparing Fenebrutinib vs ocrelizumab are so encouraging!
The wonderful podcast👇
ectrims.eu/podcast/episod…
And a summary 👇
New clinical trial
A Pilot Study of Ublituximab in People With MS Experiencing Wearing Off Phenomena While Receiving Treatment With Ocrelizumab
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
A Pilot Study of Ublituximab in People With MS Experiencing Wearing Off Phenomena While Receiving Treatment With Ocrelizumab
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
A Pilot Study of Ublituximab in People With MS Experiencing Wearing Off Phenomena While Receiving Treatment With Ocrelizumab
Clinical trial related to Multiple Sclerosis.
clinicaltrials.gov
February 6, 2026 at 8:00 AM
New clinical trial
A Pilot Study of Ublituximab in People With MS Experiencing Wearing Off Phenomena While Receiving Treatment With Ocrelizumab
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
A Pilot Study of Ublituximab in People With MS Experiencing Wearing Off Phenomena While Receiving Treatment With Ocrelizumab
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
#MS_Selfie Q&A 141: neutropaenia on ocrelizumab
Have any of you developed low neutrophil counts on ocrelizumab or the other anti-CD20 therapies? Did it resolve and/or recur? How was it managed? Did your neurologist stop your treatment? => buff.ly/OxfIWi2
Have any of you developed low neutrophil counts on ocrelizumab or the other anti-CD20 therapies? Did it resolve and/or recur? How was it managed? Did your neurologist stop your treatment? => buff.ly/OxfIWi2
Q&A 141: neutropaenia on ocrelizumab
Have any of you developed low neutrophil counts on ocrelizumab or the other anti-CD20 therapies? Did it resolve and/or recur? How was it managed? Did your neurologist stop your treatment?
gavingiovannoni.substack.com
January 27, 2026 at 4:38 PM
#MS_Selfie Q&A 141: neutropaenia on ocrelizumab
Have any of you developed low neutrophil counts on ocrelizumab or the other anti-CD20 therapies? Did it resolve and/or recur? How was it managed? Did your neurologist stop your treatment? => buff.ly/OxfIWi2
Have any of you developed low neutrophil counts on ocrelizumab or the other anti-CD20 therapies? Did it resolve and/or recur? How was it managed? Did your neurologist stop your treatment? => buff.ly/OxfIWi2
New clinical trial
Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis (BLOOMS):
a randomized controlled trial
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis (BLOOMS):
a randomized controlled trial
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis (BLOOMS):
a randomized controlled trial
Clinical trial related to Multiple Sclerosis.
euclinicaltrials.eu
January 27, 2026 at 8:00 AM
New clinical trial
Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis (BLOOMS):
a randomized controlled trial
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis (BLOOMS):
a randomized controlled trial
#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
And Reinaldo Uribe-San-Martin at the Pontificia Universidad Católica de Chile, Hospital Sótero del Río and Central Metropolitan Health Service offers new insight into how ocrelizumab performs outside clinical trials.
When Real-World Evidence Reshapes Multiple Sclerosis Care in Latin America – The Science Matters
How MS treatment performs beyond clinical trials. What happens when a high efficacy MS therapy is tested in real patients across years of routine care?
thesciencematters.org
January 20, 2026 at 9:45 AM
And Reinaldo Uribe-San-Martin at the Pontificia Universidad Católica de Chile, Hospital Sótero del Río and Central Metropolitan Health Service offers new insight into how ocrelizumab performs outside clinical trials.
"Patients would come in and say, “Oh, I have crap gap.” I remember the first few times I thought, “What is this crap gap?” The patients are talking about it on social media, but when we Googled it, the only reference we could find to it was on Reddit."
www.ijmsc.org/view/ijmsc-a...
#ocrelizumab
www.ijmsc.org/view/ijmsc-a...
#ocrelizumab
January 8, 2026 at 3:48 PM
"Patients would come in and say, “Oh, I have crap gap.” I remember the first few times I thought, “What is this crap gap?” The patients are talking about it on social media, but when we Googled it, the only reference we could find to it was on Reddit."
www.ijmsc.org/view/ijmsc-a...
#ocrelizumab
www.ijmsc.org/view/ijmsc-a...
#ocrelizumab
Ocrelizumab number two done ✔️
Here is a selection of amazing #art from the staff gallery at Charing Cross Hospital and the Imperial College Trust - grateful for amazing doctors, nurses and hospital staff 🙏🏼
❤️
#ocrevus
#gratitude
#gallery
#ms
#ocrelizumab
Here is a selection of amazing #art from the staff gallery at Charing Cross Hospital and the Imperial College Trust - grateful for amazing doctors, nurses and hospital staff 🙏🏼
❤️
#ocrevus
#gratitude
#gallery
#ms
#ocrelizumab
December 29, 2025 at 4:12 PM
Ocrelizumab number two done ✔️
Here is a selection of amazing #art from the staff gallery at Charing Cross Hospital and the Imperial College Trust - grateful for amazing doctors, nurses and hospital staff 🙏🏼
❤️
#ocrevus
#gratitude
#gallery
#ms
#ocrelizumab
Here is a selection of amazing #art from the staff gallery at Charing Cross Hospital and the Imperial College Trust - grateful for amazing doctors, nurses and hospital staff 🙏🏼
❤️
#ocrevus
#gratitude
#gallery
#ms
#ocrelizumab
🧠 Can the gut affect how well multiple sclerosis treatment works? New Czech research says yes.
📄 Ocrelizumab transiently alters microbiota and modulates immune response depending on treatment outcome; Coufal, S. et al. iScience (2025)
www.sciencedirect.com/science/arti...
📄 Ocrelizumab transiently alters microbiota and modulates immune response depending on treatment outcome; Coufal, S. et al. iScience (2025)
www.sciencedirect.com/science/arti...
December 17, 2025 at 1:16 PM
🧠 Can the gut affect how well multiple sclerosis treatment works? New Czech research says yes.
📄 Ocrelizumab transiently alters microbiota and modulates immune response depending on treatment outcome; Coufal, S. et al. iScience (2025)
www.sciencedirect.com/science/arti...
📄 Ocrelizumab transiently alters microbiota and modulates immune response depending on treatment outcome; Coufal, S. et al. iScience (2025)
www.sciencedirect.com/science/arti...
“A single immune signal predicting 2-year #MS outcomes?😮🔍”
High #TNF mRNA = greater disability progression under #Ocrelizumab! @mdpiopenaccess.bsky.social
#Immunology #MSScience #TranslationalResearch
Check the findings + share 🔗
www.mdpi.com/1422-0067/26...
High #TNF mRNA = greater disability progression under #Ocrelizumab! @mdpiopenaccess.bsky.social
#Immunology #MSScience #TranslationalResearch
Check the findings + share 🔗
www.mdpi.com/1422-0067/26...
December 15, 2025 at 7:10 AM
“A single immune signal predicting 2-year #MS outcomes?😮🔍”
High #TNF mRNA = greater disability progression under #Ocrelizumab! @mdpiopenaccess.bsky.social
#Immunology #MSScience #TranslationalResearch
Check the findings + share 🔗
www.mdpi.com/1422-0067/26...
High #TNF mRNA = greater disability progression under #Ocrelizumab! @mdpiopenaccess.bsky.social
#Immunology #MSScience #TranslationalResearch
Check the findings + share 🔗
www.mdpi.com/1422-0067/26...
Clinical trials using surrogate markers shows promising results with glatiramer acetate, Fingolimod, Siponimod, natalizumab, alemtuzumab, and ocrelizumab. However, there’s insufficient proof to claim that changes in these surrogate markers can be
explained by remyelination alone.
explained by remyelination alone.
onlinelibrary.wiley.com
December 13, 2025 at 10:00 AM
Clinical trials using surrogate markers shows promising results with glatiramer acetate, Fingolimod, Siponimod, natalizumab, alemtuzumab, and ocrelizumab. However, there’s insufficient proof to claim that changes in these surrogate markers can be
explained by remyelination alone.
explained by remyelination alone.
Ever wondered why some #MS patients thrive on #Ocrelizumab while others don’t? 👀🧬”
Baseline #TNF levels in #PBMCs quietly forecast treatment failure!📉 @mdpiopenaccess.bsky.social #MSResearch #Ocrelizumab #PrecisionMedicine
Dive in + share 👇
www.mdpi.com/1422-0067/26...
Baseline #TNF levels in #PBMCs quietly forecast treatment failure!📉 @mdpiopenaccess.bsky.social #MSResearch #Ocrelizumab #PrecisionMedicine
Dive in + share 👇
www.mdpi.com/1422-0067/26...
December 12, 2025 at 7:42 AM
Ever wondered why some #MS patients thrive on #Ocrelizumab while others don’t? 👀🧬”
Baseline #TNF levels in #PBMCs quietly forecast treatment failure!📉 @mdpiopenaccess.bsky.social #MSResearch #Ocrelizumab #PrecisionMedicine
Dive in + share 👇
www.mdpi.com/1422-0067/26...
Baseline #TNF levels in #PBMCs quietly forecast treatment failure!📉 @mdpiopenaccess.bsky.social #MSResearch #Ocrelizumab #PrecisionMedicine
Dive in + share 👇
www.mdpi.com/1422-0067/26...
“What if one #Cytokine could predict who benefits from #Ocrelizumab? 🤔🔥”
High #TNF mRNA at baseline = higher #MS activity after 24 months!📈 @mdpiopenaccess.bsky.social
#MultipleSclerosis #Neuroimmunology #Biomarkers
Read more & share 👉
www.mdpi.com/1422-0067/26...
High #TNF mRNA at baseline = higher #MS activity after 24 months!📈 @mdpiopenaccess.bsky.social
#MultipleSclerosis #Neuroimmunology #Biomarkers
Read more & share 👉
www.mdpi.com/1422-0067/26...
December 10, 2025 at 7:28 AM
“What if one #Cytokine could predict who benefits from #Ocrelizumab? 🤔🔥”
High #TNF mRNA at baseline = higher #MS activity after 24 months!📈 @mdpiopenaccess.bsky.social
#MultipleSclerosis #Neuroimmunology #Biomarkers
Read more & share 👉
www.mdpi.com/1422-0067/26...
High #TNF mRNA at baseline = higher #MS activity after 24 months!📈 @mdpiopenaccess.bsky.social
#MultipleSclerosis #Neuroimmunology #Biomarkers
Read more & share 👉
www.mdpi.com/1422-0067/26...
First Reported Case of Ocrelizumab-Associated Leukocytoclastic Vasculitis in Primary Progressive Multiple Sclerosis: A Case Report
First Reported Case of Ocrelizumab-Associated Leukocytoclastic Vasculitis in Primary Progressive Multiple Sclerosis: A Case Report - PubMed
This case is the first reported instance of LCV associated with ocrelizumab in the treatment of multiple sclerosis. It underscores the need for awareness of potential drug-induced vasculitis in patients undergoing new or modified treatments and contributes to the growing understanding of adverse eff …
pubmed.ncbi.nlm.nih.gov
December 10, 2025 at 1:11 AM
First Reported Case of Ocrelizumab-Associated Leukocytoclastic Vasculitis in Primary Progressive Multiple Sclerosis: A Case Report
New post: Ocrelizumab inhibits MS by microbiota https://multiple-sclerosis-research.org/2025/12/ocrelizumab-inhibits-ms-by-microbiota/
December 8, 2025 at 9:48 PM
New post: Ocrelizumab inhibits MS by microbiota https://multiple-sclerosis-research.org/2025/12/ocrelizumab-inhibits-ms-by-microbiota/
Infusion day! First time with the team at UT and they’re awesome and kind. Which is nice, as it’s stressful and I loved my nurses at Walter Reed.
Go go Ocrelizumab! Punch my immune system in the nards!
Go go Ocrelizumab! Punch my immune system in the nards!
December 8, 2025 at 5:17 PM
Infusion day! First time with the team at UT and they’re awesome and kind. Which is nice, as it’s stressful and I loved my nurses at Walter Reed.
Go go Ocrelizumab! Punch my immune system in the nards!
Go go Ocrelizumab! Punch my immune system in the nards!
“Could a blood-based #TNF signature reshape #MS therapy decisions?💡🩸⚡️” High baseline TNF linked to more disease activity on #Ocrelizumab! @mdpiopenaccess.bsky.social
#NeuroScience #ClinicalResearch Read, share, spread the insight!🔥
www.mdpi.com/1422-0067/26...
#NeuroScience #ClinicalResearch Read, share, spread the insight!🔥
www.mdpi.com/1422-0067/26...
December 8, 2025 at 6:59 AM
“Could a blood-based #TNF signature reshape #MS therapy decisions?💡🩸⚡️” High baseline TNF linked to more disease activity on #Ocrelizumab! @mdpiopenaccess.bsky.social
#NeuroScience #ClinicalResearch Read, share, spread the insight!🔥
www.mdpi.com/1422-0067/26...
#NeuroScience #ClinicalResearch Read, share, spread the insight!🔥
www.mdpi.com/1422-0067/26...
Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Real-World Evidence Study Using Registry-Linked Electronic Health Records #NeuroDegeneration 🧪🧠
https://www.medrxiv.org/content/10.64898/2025.12.01.25341331v1
https://www.medrxiv.org/content/10.64898/2025.12.01.25341331v1
December 4, 2025 at 5:02 PM
Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Real-World Evidence Study Using Registry-Linked Electronic Health Records #NeuroDegeneration 🧪🧠
https://www.medrxiv.org/content/10.64898/2025.12.01.25341331v1
https://www.medrxiv.org/content/10.64898/2025.12.01.25341331v1
Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Real-World Evidence Study Using Registry-Linked Electronic Health Records #NeuroDegeneration 🧪🧠
http://medrxiv.org/cgi/content/short/10.64898/2025.12.01.25341331v1
http://medrxiv.org/cgi/content/short/10.64898/2025.12.01.25341331v1
December 3, 2025 at 8:02 AM
Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Real-World Evidence Study Using Registry-Linked Electronic Health Records #NeuroDegeneration 🧪🧠
http://medrxiv.org/cgi/content/short/10.64898/2025.12.01.25341331v1
http://medrxiv.org/cgi/content/short/10.64898/2025.12.01.25341331v1
Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Real-World Evidence Study Using Registry-Linked Electronic Health Records https://www.medrxiv.org/content/10.64898/2025.12.01.25341331v1
December 3, 2025 at 6:25 AM
Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Real-World Evidence Study Using Registry-Linked Electronic Health Records https://www.medrxiv.org/content/10.64898/2025.12.01.25341331v1
“A single immune signal predicting 2-year #MS outcomes?😮🔍” High #TNF mRNA = greater disability progression under #Ocrelizumab! @IJMS_MDPI @mdpiopenaccess.bsky.social
#Immunology #MSScience #TranslationalResearch
Check the findings + share! 🔗
www.mdpi.com/1422-0067/26...
#Immunology #MSScience #TranslationalResearch
Check the findings + share! 🔗
www.mdpi.com/1422-0067/26...
December 1, 2025 at 6:48 AM
“A single immune signal predicting 2-year #MS outcomes?😮🔍” High #TNF mRNA = greater disability progression under #Ocrelizumab! @IJMS_MDPI @mdpiopenaccess.bsky.social
#Immunology #MSScience #TranslationalResearch
Check the findings + share! 🔗
www.mdpi.com/1422-0067/26...
#Immunology #MSScience #TranslationalResearch
Check the findings + share! 🔗
www.mdpi.com/1422-0067/26...
“Ever wondered why some #MS patients thrive on #Ocrelizumab while others don’t? 👀🧬”
Baseline #TNF levels in #PBMCs quietly forecast treatment failure!📉 @mdpiopenaccess.bsky.social #MSResearch #Ocrelizumab #PrecisionMedicine
Dive in + share 👇
www.mdpi.com/1422-0067/26...
Baseline #TNF levels in #PBMCs quietly forecast treatment failure!📉 @mdpiopenaccess.bsky.social #MSResearch #Ocrelizumab #PrecisionMedicine
Dive in + share 👇
www.mdpi.com/1422-0067/26...
November 27, 2025 at 10:19 AM
“Ever wondered why some #MS patients thrive on #Ocrelizumab while others don’t? 👀🧬”
Baseline #TNF levels in #PBMCs quietly forecast treatment failure!📉 @mdpiopenaccess.bsky.social #MSResearch #Ocrelizumab #PrecisionMedicine
Dive in + share 👇
www.mdpi.com/1422-0067/26...
Baseline #TNF levels in #PBMCs quietly forecast treatment failure!📉 @mdpiopenaccess.bsky.social #MSResearch #Ocrelizumab #PrecisionMedicine
Dive in + share 👇
www.mdpi.com/1422-0067/26...
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
https://www.europesays.com/ie/202013/
Ocrelizumab (Ocrevus; Genentech) appears to have a more favorable safety profile in patients with multiple sclerosis (MS) compared…
https://www.europesays.com/ie/202013/
Ocrelizumab (Ocrevus; Genentech) appears to have a more favorable safety profile in patients with multiple sclerosis (MS) compared…
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS - Ireland
Ocrelizumab (Ocrevus; Genentech) appears to have a more favorable safety profile in patients with multiple sclerosis (MS) compared to rituximab (Rituxan;
www.europesays.com
November 26, 2025 at 11:45 PM
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
https://www.europesays.com/ie/202013/
Ocrelizumab (Ocrevus; Genentech) appears to have a more favorable safety profile in patients with multiple sclerosis (MS) compared…
https://www.europesays.com/ie/202013/
Ocrelizumab (Ocrevus; Genentech) appears to have a more favorable safety profile in patients with multiple sclerosis (MS) compared…
“What if one #Cytokine could predict who benefits from #Ocrelizumab? 🤔🔥”
High #TNF mRNA at baseline = higher #MS activity after 24 months!📈 @mdpiopenaccess.bsky.social
#MultipleSclerosis #Neuroimmunology #Biomarkers
Read more & share 👉
www.mdpi.com/1422-0067/26...
High #TNF mRNA at baseline = higher #MS activity after 24 months!📈 @mdpiopenaccess.bsky.social
#MultipleSclerosis #Neuroimmunology #Biomarkers
Read more & share 👉
www.mdpi.com/1422-0067/26...
November 24, 2025 at 6:43 AM
“What if one #Cytokine could predict who benefits from #Ocrelizumab? 🤔🔥”
High #TNF mRNA at baseline = higher #MS activity after 24 months!📈 @mdpiopenaccess.bsky.social
#MultipleSclerosis #Neuroimmunology #Biomarkers
Read more & share 👉
www.mdpi.com/1422-0067/26...
High #TNF mRNA at baseline = higher #MS activity after 24 months!📈 @mdpiopenaccess.bsky.social
#MultipleSclerosis #Neuroimmunology #Biomarkers
Read more & share 👉
www.mdpi.com/1422-0067/26...
#MS_Selfie Q&A 125: ocrelizumab failures
Almost all of the investigators testing lower doses of anti-CD20 therapies against licensed therapies are conflicted by wanting to save money. Do you agree? => buff.ly/8o9pPV9
Almost all of the investigators testing lower doses of anti-CD20 therapies against licensed therapies are conflicted by wanting to save money. Do you agree? => buff.ly/8o9pPV9
Q&A 125: ocrelizumab failures
Almost all of the investigators testing lower doses of anti-CD20 therapies against licensed therapies are conflicted by wanting to save money.
gavingiovannoni.substack.com
November 22, 2025 at 9:47 AM
#MS_Selfie Q&A 125: ocrelizumab failures
Almost all of the investigators testing lower doses of anti-CD20 therapies against licensed therapies are conflicted by wanting to save money. Do you agree? => buff.ly/8o9pPV9
Almost all of the investigators testing lower doses of anti-CD20 therapies against licensed therapies are conflicted by wanting to save money. Do you agree? => buff.ly/8o9pPV9